Next Article in Journal
Abdominal Desmoid: Course, Severe Outcomes, and Unique Genetic Background in a Large Local Series
Previous Article in Journal
Anastasis: Return Journey from Cell Death
Previous Article in Special Issue
Combining Oncolytic Viruses and Small Molecule Therapeutics: Mutual Benefits
Editorial

Oncolytic Virus Immunotherapy

1
Laboratory of Oncolytic Virus Immuno-Therapeutics, Luxembourg Institute of Health, 84 Val Fleuri, L-1526 Luxembourg, Luxembourg
2
German Cancer Research Centre, Laboratory of Oncolytic Virus Immuno-Therapeutics, Im Neuenheimer Feld 242, 69120 Heidelberg, Germany
3
Cancer Therapeutics Program, Ottawa Hospital Research Institute, Ottawa, ON K1H 8L6, Canada
4
Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, ON K1H 8M5, Canada
5
Institute of Cancer Research, London SW3 6JB, UK
*
Author to whom correspondence should be addressed.
Cancers 2021, 13(15), 3672; https://doi.org/10.3390/cancers13153672
Received: 12 May 2021 / Accepted: 7 July 2021 / Published: 22 July 2021
(This article belongs to the Special Issue Oncolytic Virus Immunotherapy)
Note: In lieu of an abstract, this is an excerpt from the first page.

Oncolytic viruses (OVs) were originally developed as direct cytotoxic agents but have been increasingly recognised as a form of immunotherapy [...] View Full-Text
MDPI and ACS Style

Marchini, A.; Ilkow, C.S.; Melcher, A. Oncolytic Virus Immunotherapy. Cancers 2021, 13, 3672. https://doi.org/10.3390/cancers13153672

AMA Style

Marchini A, Ilkow CS, Melcher A. Oncolytic Virus Immunotherapy. Cancers. 2021; 13(15):3672. https://doi.org/10.3390/cancers13153672

Chicago/Turabian Style

Marchini, Antonio, Carolina S. Ilkow, and Alan Melcher. 2021. "Oncolytic Virus Immunotherapy" Cancers 13, no. 15: 3672. https://doi.org/10.3390/cancers13153672

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop